U.S. Patient and Trademark Office Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		09902475
Filing Date		2001-07-09
First Named Inventor	Briere	e
Art Unit		1722
Examiner Name Davis		s, Robert B.
Attorney Docket Number		011496.236625

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue C	)ate	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	3861640		1975-0	1-21	Agneta		Whole	Document	
	2	3978910		1976-0	9-07	Gladwin		Whole	Document	
	3	4032278		1977-0	6-28	Kuenzig et al		Whole	Document	
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date Name of Patentee or Applicant of cited Document		Releva	Columns,Lines when ant Passages or Rele s Appear			
	1									
If you wis	h to a	d additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ada	d button	Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	or	Pages,Columns,Line where Relevant Passages or Relevan Figures Appear	\
	1									[

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09902475		
Filing Date		2001-07-09		
First Named Inventor	Briere			
Art Unit		1722		
Examiner Name	Davis	s, Robert B.		
Attorney Docket Number		011496 236625		

If you wish	h to a	dd add	ditional Foreign Patent Document citation information please click the Add button Add					
			NON-PATENT LITERATURE DOCUMENTS Remove					
Examiner Initials* Cite Initials* Ci								
	1							
If you wisl	If you wish to add additional non-patent literature document citation information please click the Add button Add							
			EXAMINER SIGNATURE					
Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

See Kinz Codes of USPTO Planto Documents at year, USPTO (2007 or MFEP 991.04. \* Enter office and issued the document, by the two letter code (WIPO Standard ST3.). \* For Legamene patient document, be included on the year of the eight or the Engeror must provide the estain funder for the patient document.

\*I Kind of Courners by the appropriate symbols as indicated on the document under WIPO Standard ST,168 possible. \* Applicant is to place a check mark here if English thanquage translations an althoride.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09902475		
	Filing Date		2001-07-09		
First Named Inventor Briefe		Brien			
	Art Unit		1722		
	Examiner Name	Davis	, Robert B.		
	Attorney Docket Number		011496.236625		

#### CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV1).

## OR

That no item of information contained in the information disclosure statement was clied in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification and a contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than these months point to the filing of the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than these months point to the filing of the information disclosure statement was considered to the contraction of the contrac

See attached certification statement.

J. Scott Anderson

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1 97 and 1 98 to make the appropriate selection/s):

### □ None

Name/Print

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

48563

form of the aignature.							
Signature	/J. Scott Anderson/	Date (YYYY-MM-DD)	2006-05-02				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operament of Commence, P. 0. Box 1450, Alexandris, V.2.231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. (2)(2)(2) farmishing of the information solicide to is columbary, and (3) the primoral pursues for which the information is used by the U.S. Patient and Trademan (Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested requirement of the patient of the patient application or patient. If you do not furnish the requested requirement of the patient application or patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C.552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- . A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was fied in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application part to published application, an application part to put to published application, an application.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.